J&J Makes Cuts In Bid To Strengthen Ailing Medtech Business
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson is cutting 4% to 6% of its global medical device business workforce in an effort to turn around weak performance. The cuts will come from its orthopedics, surgery and cardiovascular units, but the proportion of reductions per business and details on which product segments J&J might be looking to drop altogether were not disclosed.